本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
NEW CLARK CITY, Philippines, Feb. 12, 2026 /PRNewswire/ -- AGX Group Berhad ("AGX" or the "Company") a regional logistics and freight forwarding solutions provider, today announced changes to its organisational structure as part of its leadership development and growth strategy. Under the new structure, Mr. Maximino Baylen Gulmayo, Jr. ("Mr Maximino"), currently the Country Managing Director of AGX Express Phils. Inc. ("AGX Philippines"), has been appointed as the Group's Chief Commercial Officer ("CCO"). In this role, Mr Maximino will oversee the Group's commercial strategy, business development initiatives, and key customer relationships, supporting AGX's regional expansion. The Company had, on 10 February 2026, received a Letter of Confirmation dated 9 February 2026 from Mr Maximino, confirming his acceptance of the offer of promotion to the position of CCO. Following Mr Maximino's appointment, he has relinquished his role as Country Managing Director of AGX Philippines. The position will be succeeded by Mr Aldrich P. Espino ("Mr Aldrich"), currently Senior General Manager of AGX Philippines. Mr Aldrich will lead the AGX Philippines' operations, a key regional market. Mr Aldrich Mr Aldrich is a Certified Public Accountant (CPA) and a pioneer employee of AGX Philippines, having joined the company in 2013. He has held key roles across finance, operations, and sales, most recently as Senior General Manager for Sales and Customer Service. His cross functional experience and institutional knowledge position him to lead AGX Philippines into its next phase of growth. Mr Maximino Mr Maximino holds a Bachelor of Science in Customs Administration from John B. Lacson Colleges Foundation, Philippines. With more than three decades of experience spanning domestic shipping, air and sea freight, customs brokerage, and road transport, he co-founded AGX Philippines in 2012 and driven the expansion of the Group's logistics network and operational capabilities in the Philippines. Commenting on the leadership appointments, Dato' Ponnudorai A/L Periasamy, AGX's Group Chief Executive Officer, said: "These appointments reflect our recognition of proven capability, long-term commitment, and consistent performance within the Group. Mr Maximino has played a pivotal role in building AGX Philippines into a key growth engine and his appointment allows us to leverage his commercial leadership at the Group level. Mr Aldrich's promotion reflects our strong talent pipeline and succession planning." The organisational realignment underscores AGX Group's commitment to strengthening leadership depth, ensuring continuity in key markets, and supporting sustainable growth as the Group continues to scale its regional operations.
Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating Officer Five new Vice Presidents appointed, underscoring our commitment to leadership development VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen the capabilities and experience of the organization. These updates are designed to align key leadership roles with the Company’s corporate strategy announced in November. “At Zymeworks, we recognize that our greatest asset is our people. Ensuring that we continue to have the right set of key skills and experience within our Board of Directors and leadership team is critical for successful execution of our current strategy and driving long-term shareholder value. Elevating talented individuals at Zymeworks recognizes their strong performance for the Company, our continued confidence in their abilities and the emphasis we place on cultivating leaders from within,” said Kenneth Galbraith, Chair, Chief Executive Officer, and Acting Chief Financial Officer of Zymeworks. Board of Directors Strengthened to Support Future Strategy Brian Cherry has been appointed to the Board effective January 12, 2026 to bring the current Board to nine directors. Mr. Cherry has spent more than 25 years investing in and helping build businesses across a wide range of industries including healthcare, industrials, business services, financial services, and consumer products. He has led buyout and growth equity investments in companies totaling over $25 billion in enterprise value. Previously, Mr. Cherry was a Managing Partner at Oak Hill Capital, a private equity firm. His board experience includes over a dozen private and public companies, the U.S. Air Force Academy Foundation, and the Undergraduate Financial Aid Leadership Council at the University of Pennsylvania. Mr. Cherry earned his BA from Princeton University and his MBA from The Wharton School at the University of Pennsylvania. Mr. Galbraith added, “Over the past year, we have taken deliberate steps to streamline the Board, reducing its size from twelve to nine directors, while ensuring that the collective skills and experience of the Board are well aligned to provide effective oversight of the Company’s new corporate strategy. Brian brings complementary expertise to the Board, particularly in capital allocation and strategic acquisitions, which we believe will support disciplined execution and long-term shareholder value creation.” Mr. Cherry is the fourth new director appointed to Zymeworks’ Board over the past twelve months, joining Mr. Oleg Nodelman, Mr. Greg Ciongoli, and Mr. Robert E. Landry. Leadership Appointments and Transitions Position Company for Next Phase of Growth Mr. Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer with expanded responsibilities beyond his current leadership of Technology and Manufacturing Operations, Quality, and Alliance/Program Management. Dr. Sabeen Mekan has been promoted to Senior Vice President and Chief Medical Officer (CMO) effective February 1, 2026, with overall responsibility for our clinical development, regulatory affairs, pharmacovigilance/patient safety, and clinical operations. Dr. Jeff Smith, our current CMO, will be retiring effective January 31, 2026, while continuing to provide services as an adviser for a transitional time period. Ms. Leone Patterson, our Chief Financial and Business Officer and Mr. Daniel Dex, General Counsel, will both be departing from their roles at Zymeworks during the first quarter of 2026. The Company has commenced a comprehensive search for a permanent Chief Financial Officer with the experience required to support the Company’s next phase of development. Mr. Galbraith has assumed the role of Acting Chief Financial Officer until a replacement is secured. In addition, the following individuals have been promoted or appointed to the leadership team: Ms. Laura O’Connor, Senior Vice President and Chief Human Resources Officer Ms. Bijal Desai, Senior Vice President, Finance Dr. Lindsey Foulkes, Senior Vice President, Corporate Development and Strategy Dr. Charles Chen, Vice President, Translational Sciences Ms. Shrinal Inamdar, Vice President, Investor Relations Ms. Diana Papove, Vice President, Corporate Communications Ms. Victoria Spencer, Vice President, Treasury and Tax Dr. Lingxing Zheng, Vice President, Regulatory Affairs “These outstanding individuals have consistently demonstrated exceptional leadership abilities, commitment to our vision, and a deep understanding of both our strategic objectives and our commitment to bringing meaningful medicines to patients worldwide,” stated Mr. Galbraith. “These leadership changes reflect the alignment of management resources to effectively execute against our strategic objectives in order to drive long-term shareholder value at Zymeworks.” Additional information on the background and experience of these individuals is available on the Company’s website at www.zymeworks.com. About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Cautionary Note Regarding Forward-Looking Statements This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ expectations regarding implementation of its strategic priorities and the anticipated benefits thereof; implementation of its evolving asset aggregation strategy, including existing and potential future royalty streams and existing and potential new partnerships; statements that relate to the expected contributions of personnel to Zymeworks’ strategic goals and long-term shareholder value; anticipated capital allocation strategy; industry opportunities for acquisition of new revenue streams or collaborations; the commercial potential of technology platforms and product candidates; Zymeworks’ early-stage pipeline and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ evolution of its business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Investor inquiries:Shrinal InamdarVice President, Investor Relations(604) 678-1388ir@zymeworks.com Media inquiries:Diana PapoveVice President, Corporate Communications(604) 678-1388media@zymeworks.com
SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Automic Group, Australia's market leader in technology-driven investor administration and services, announces two senior executive appointments to drive further growth and accelerate the Group's strategy. Stacey Kelly had been appointed Chief Financial Officer (CFO). Stacey is an experienced CFO with more than 25 years' experience across software, fund administration, wealth management technology, and financial services. She is known for her strategic and operational experience, partnership approach in driving aligned outcomes and supporting CEOs, leadership teams and the broader organisation. Before joining Automic, Stacey was CFO at GBST, where she led the global finance function with cross jurisdictional responsibility across multiple markets, supporting the investment program to deliver a full platform cloud transformation under private equity ownership. Prior experience includes her role as CFO at ASX-listed Mainstream (acquired by private equity backed Apex Group), and roles at ASX-listed Macquarie Group and LSE-listed HSBC. Simone Shugg has been appointed Chief People Officer (CPO). Simone is an experienced CPO who has spent more than two decades helping organisations navigate growth, transformation and change. She is known for aligning people, culture and operating models with ambitious commercial goals, and for working as a true partner to CEOs, executive teams and boards. Before joining Automic, Simone was CPO at private equity owned Nearmap, where she led the global people strategy through rapid international expansion, organisational restructuring and the company's transition to private equity ownership. She has also held senior executive roles at Foxtel as Executive Director, People & Culture, and at Carnival Australia as Vice President, People & Performance, supporting large, complex workforces through industry disruption, digitisation and major change programs. These key senior appointments follow the acquisition of Automic by Advent, a leading global private equity investor. "I'm delighted to welcome Stacey and Simone to Automic. Each brings a depth of leadership experience that will be central to enabling our next phase of growth as we advance our market leadership domestically, pursue global opportunities and continue to innovate client-focused solutions," said David Raper, CEO of Automic. "Combined with our three new independent board appointments and the support of Advent, we have significant global expertise and depth of experience to drive our business forward at scale." "I'm excited to be joining Automic, a technology-led market leader in investor administration services, with the opportunity to support further expansion and investment leveraging my prior experience across technology-led financial services companies. The business has a clear vision and value-creation plan, and I believe that strength in finance, and close partnerships with the leadership team and broader business will accelerate delivering on Automic's potential," newly appointed Automic CFO Stacey Kelly said. "I'm thrilled to join as Chief Financial Officer and look forward to working with David and the leadership team to support the delivery of our vision for our customers, staff and other stakeholders." "What excites me about Automic is the opportunity to combine a strong commercial story with a genuine focus on people. The business is growing quickly, with a clear value-creation agenda, and I firmly believe that leadership, culture and talent will be critical to delivering on that ambition," newly appointed Automic CPO Simone Shugg said. "I'm delighted to join as Chief People Officer and to work with David and the leadership team to make sure our people strategy is a true driver of performance – creating an environment where our teams can do their best work and continue to push the boundaries of what we deliver for clients." About Automic Group Automic Group is Australia's market leader in technology-driven investor administration. Combining proprietary cloud-native technology with expert service, Automic simplifies investor administration and governance for companies and funds. It provides the market's leading registry, employee share plans, IR analytics, and fund administration services for over 1,400 ASX-listed and unlisted organisations. Founded to challenge an industry reliant on outdated systems, Automic is committed to delivering smarter, more efficient, and secure solutions that help Australia's companies and fund managers. For more information visit www.automicgroup.com.au Media Contact: Gareth Stewart | Gareth.stewart@automicgroup.com.au
SINGAPORE, Nov. 24, 2025 /PRNewswire/ -- Zenika Singapore today announced the appointment of Seet Teck Kiang as Head of Business and the return of Michael Isvy as Head of Engineering. These two strategic leadership hires reinforce Zenika's ambition to expand its regional footprint while scaling the impact of its AI Multiplier Framework — the company's holistic model for delivering high-performance AI across products, architecture, and operations. L-R - Michael Isvy, Head of Engineering and Seet Teck Kiang, Head of Business at Zenika Singapore Seet Teck Kiang Joins as Head of Business A seasoned transformation leader with over two decades of experience, Seet Teck Kiang brings deep expertise across Asia's enterprise and public-sector landscapes. A graduate of the National University of Singapore, Seet has held senior positions at ThoughtWorks, EPAM Systems, and Zühlke Group, where he guided clients through platform modernisation, digital transformation, and large-scale strategic initiatives. Seet's appointment aligns with Zenika's ambition to scale its AI Multiplier FrameworkTM (SHAPE × SHIP × SYNC) — a comprehensive approach that unifies product engineering, AI-boosted delivery, and cloud-native architectures to help organisations move beyond experimental AI toward sustained business value. "What attracted me to Zenika is its ethos of engineering excellence and its ability to bring AI, product, architecture, and operations together with real discipline ," Seet said. "The AI Multiplier Framework is a practical and powerful way to scale AI impact, and I look forward to accelerating Zenika's growth across Asia using this model." Michael Isvy Joins as Head of Engineering Zenika also welcomes back Michael Isvy, who helped found Zenika Singapore a few years ago. Michael returns to lead the company's Engineering and AI strategy, focusing on scaling augmented development practices, rationalising AI usage, and industrialising AI workflows to support complex, real-world delivery. With a career shaped across two engineering cultures — France's heritage of rigorous craftsmanship and Singapore's fast-paced innovation ecosystem — Michael brings a rare ability to bridge teams, practices, and delivery methodologies. His new mission: transform our Singapore division into Zenika's living lab for AI engineering, enhancing collaboration with French teams and accelerating technical excellence across the group. "Returning to Zenika is about reconnecting the two cultures that shaped my approach to engineering ," Michael said. "My goal is to turn our Singapore division into a true experimentation hub for AI adoption — making AI more reliable, more useful, and more accessible for our engineers and clients." Welcoming the dual appointments, Timothée Dufresne, MD of Zenika Singapore, said: "Seet and Michael each bring exceptional strengths that perfectly complement Zenika's ambitions for the next decade. Seet strengthens our business strategy and regional growth, while Michael elevates our engineering and AI capabilities. Together, they will drive the expansion and shape the next chapter of Zenika Singapore and Asia. " About Zenika: Founded in 2006, Zenika is a digital services boutique specialising in business transformation, IT modernisation, and innovation, with over 530 experts across 14 offices globally. Zenika Singapore is the Asia-Pacific arm of Zenika. It works with enterprises, government agencies, and emerging tech innovators to design, build, and scale modern digital products and platforms.
Joachim Hanssen appointed Chief Executive Officer, Asia Pacific (APAC), effective August 1, 2025 Alberto Martinez appointed Chief Executive Officer, Europe (EU), effective October 1, 2025 Renee Toh to succeed Martinez as Vice President Global Ocean Freight, effective September 25, 2025 SINGAPORE - Media OutReach Newswire - 6 August 2025 - The Rhenus Group today announced three strategic leadership appointments that will play a pivotal role in driving the company's next phase of growth, innovation, and regional integration. These appointments are part of a broader transformation within the Air & Ocean division of the Rhenus Group, aimed at aligning leadership with evolving market dynamics and strengthening the company's ability to deliver customer-centric solutions across key geographies. Joachim Hanssen Appointed Chief Executive Officer, Asia Pacific (APAC) Effective August 1, 2025, Joachim Hanssen has assumed the role of Chief Executive Officer, Asia Pacific (APAC). Joachim will also oversee Greater China, Central Asia & Turkey as part of his scope of work. With over two decades at Rhenus, Joachim has been instrumental in expanding the company's footprint across Asia. His leadership has been marked by operational excellence, cultural fluency, and a strong focus on regional growth. Joachim's appointment positions Rhenus to unify and scale its APAC operations with greater strategic cohesion. Alberto Martinez Appointed Chief Executive Officer, Europe (EU) Effective October 1, 2025, Alberto Martinez will take on the role of Chief Executive Officer, Europe (EU). Currently serving as Vice President Global Ocean Freight, Alberto has led the development of Rhenus' global ocean freight strategy, expanded trade lanes, and built strong carrier partnerships. His leadership has built up a global ocean freight structure, driven commercial growth and strengthened Rhenus' position as a global ocean freight forwarder. Alberto is well positioned to lead the European region, one of Rhenus' most complex and strategically vital markets, into the next phase of development. Alberto will succeed Markus Lingohr, who will retire in 2026, with a structured transition already underway. Renee Toh to Lead Global Ocean Freight Rhenus is pleased to announce the appointment of Renee Toh as Vice President Global Ocean Freight, effective September 25, 2025, succeeding Alberto Martinez. Renee brings over 20 years of global experience in ocean freight and trade management, with a strong track record in leading cross-functional teams and delivering commercially driven solutions. Prior to joining Rhenus, she covered the position as Head of Global Ocean Freight Procurement at CEVA Logistics, where she played a key role in optimizing procurement strategies and enhancing global carrier partnerships. Her appointment underscores Rhenus' commitment to strengthening its global product strategy and enhancing service delivery across international trade lanes. Strategic Leadership for a Future-Ready Organization The newly appointed leaders bring deep expertise, global perspective, and proven track records in building high-performing teams and scalable logistics solutions. Their new roles reflect Rhenus Group's commitment to investing in leadership that can translate global strategy into regional execution. "These leadership appointments reflect our long-term vision to build a more agile, integrated, and customer-focused organization. By placing experienced leaders in strategically critical roles, we are reinforcing our ability to respond to market shifts, deepen customer relationships, and unlock new opportunities across regions," said Jan Harnisch, Member of the Board – Air & Ocean. "Rhenus is pleased to announce the new appointments of Joachim and Alberto, and to welcome Renee as member of the Rhenus family, wishing each of them continued success and fulfillment in their respective roles. Their experience will be instrumental in driving our next phase of growth and integration across regions." Hashtag: #RhenusThe issuer is solely responsible for the content of this announcement.About RhenusThe Rhenus Group is one of the leading logistics specialists with global business operations and annual turnover amounting to EUR 8.2 billion. 41,000 employees work at 1,330 business sites in more than 70 countries and develop innovative solutions along the complete supply chain. Whether providing transport, warehousing, customs clearance or value-added services, the family-owned business pools its operations in various business units where the needs of customers are the major focus at all times.
Christopher Lim, previously Managing Director, Singapore, Malaysia, and Brunei, will be appointed Vice President and Head of Road Freight and Multimodal, Asia Pacific, effective 1 August 2025. Praveen Gregory, currently Senior Vice President, Ocean Freight, Asia Pacific, will succeed Christopher as Managing Director, Singapore, Malaysia, and Brunei, effective 1 August 2025 Bjoern Schoon, currently Vice President, Global Business Development, OMS and OCM, will succeed Praveen as Senior Vice President, Ocean Freight, Asia Pacific, effective 1 August 2025 SINGAPORE - Media OutReach Newswire – 14 July 2025 - DHL Global Forwarding, the freight specialist arm of DHL Group, has announced three strategic leadership appointments in Asia Pacific with the upcoming retirement of Bruno Selmoni, Vice President and Head of Road Freight and Multimodal, DHL Global Forwarding. All three appointments will be effective 1 August 2025. From L to R: Christopher Lim, Praveen Gregory, and Bjoern Schoon will assume their new appointments effective 1 August 2025 "Bruno's retirement after almost 50 years of exceptional service marks both the end of an era and the beginning of an exciting new chapter for our region. There are new openings with his retirement, and I'm proud that we have filled them with outstanding internal leaders, which clearly indicates our colleagues' drive and desire to grow within our network. Christopher, Praveen, and Bjoern each bring a powerful combination of expertise, experience, market insight, and fresh energy to their roles. These new appointments are a strategic step aligned with Strategy 2030 to accelerate sustainable growth, innovate our services, and empower our teams. I'm confident this team will drive our ambitions forward, delivering value for our customers and inspiring our colleagues to reach new heights," said Niki Frank, CEO, DHL Global Forwarding Asia Pacific. Christopher Lim appointed as Vice President and Head of Road Freight and Multimodal, DHL Global Forwarding Asia Pacific. Christopher Lim, currently Managing Director, DHL Global Forwarding Singapore, Malaysia, and Brunei, will succeed Bruno Selmoni as Vice President and Head of Road Freight and Multimodal, DHL Global Forwarding Asia Pacific. He will continue to be based in Singapore and report to Niki Frank, CEO, DHL Global Forwarding Asia Pacific. Christopher joined the DHL Group in 2004 as a Regional Account Development Manager, and has since assumed several management roles across DHL Global Forwarding. Serving clients in the telecommunications and network sector, he gained experience across various teams until he was announced as Head of Sales and Marketing of DHL Global Forwarding Hong Kong and South China in early 2013. He was promoted to Managing Director, DHL Global Forwarding Malaysia in the same year before his portfolio expanded to his current role in 2020. Praveen Gregory takes over from Christopher Lim as Managing Director of DHL Global Forwarding Singapore, Malaysia, and Brunei. With Christopher's move, Praveen Gregory, currently Senior Vice President, Ocean Freight, DHL Global Forwarding Asia Pacific, will succeed Christopher as Managing Director of DHL Global Forwarding Singapore, Malaysia, and Brunei. Praveen will continue to report directly to Niki Frank and will be based in Singapore. Praveen has extensive experience in the logistics sector. Before joining the DHL Group in Dubai Ocean Freight Operations in 2008, Praveen worked for Maersk. In 2010, he relocated to Germany and held several roles in Market Intelligence & Strategy and Product Development. He moved to Hong Kong in 2018 to take on regional management roles in Ocean Commercial Center and Account Management for Industrial Supply Chain (ISC). In 2022, he assumed the position of Vice President, Order Management Solutions Asia Pacific, before he took on his current role in 2023. Bjoern Schoon takes over from Praveen Gregory as Senior Vice President, Ocean Freight, DHL Global Forwarding Asia Pacific. Bjoern Schoon, currently Vice President, Global Business Development, Order Management Solutions (OMS) and Ocean Contract Management (OCM), DHL Global Forwarding, will succeed Praveen as Senior Vice President, Ocean Freight, DHL Global Forwarding Asia Pacific. Bjoern will relocate to Singapore and report directly to Niki Frank, with a dotted reporting line to Casper Ellerbaek, Executive Vice President and Global Head of Ocean Freight, DHL Global Forwarding. Bjoern is a seasoned logistics expert with nearly 30 years of experience in ocean freight and supply chain across key global markets. Before joining DHL, Bjoern has accumulated invaluable leadership experience in his previous roles at Kuehne+Nagel, having assumed key positions including Managing Director for Belgium and Luxembourg in 2023. for Thailand, Cambodia & Myanmar between 2016 and 2022. Before these, he held senior roles in Singapore, Malaysia, Hong Kong, and South China, with experience in sea logistics, account management and customer service. Hashtag: #DHLGroup #LogisticsLeadership #SupplyChain #OceanFreight The issuer is solely responsible for the content of this announcement.DHL – The logistics company for the world DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With approximately 400,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as "The logistics company for the world". DHL is part of DHL Group. The Group generated revenues of approximately 84.2 billion euros in 2024. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.
A12 藝術空間
Leadership Appointments
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
